Galapagos Reports Results from 10-week Analysis of Phase 2 Study with Filgotinib in Crohn's Disease

Galapagos (NASDAQ:GLPG) announced the presentation of  detailed results from the Phase 2 FITZROY study of filgotinib in Crohn’s Disease, at the 11th Congress of ECCO in Amsterdam, the Netherlands, from March 16 – 19.
According to the news:

Filgotinib is the first JAK inhibitor to show clinical efficacy in moderate to severely active Crohn’s Disease.  Furthermore, filgotinib showed improvement in quality of life (IBDQ) in TNF-naive and TNF-failure populations.  The rate of treatment-emergent adverse events was similar between the filgotinib and placebo arms; the most common adverse events occurring in each study arm were infections and infestations (26 percent vs. 23 percent), gastrointestinal disorders (24 percent vs. 23 percent) and nervous system disorders (16 percent vs. 18 percent).  The 10-week results support further development of filgotinib in inflammatory bowel disease (IBD).  Galapagos and Gilead Sciences also expect to report the full 20-week results for FITZROY in the first half of 2016.

Click here to view the full news release.